International Travel Recovery and Expanding Immunization Requirements Increase Demand for Travelers Vaccines Worldwide

NEW YORK, June 11, 2026 - The global Travelers Vaccines market was valued at USD 6.43 Billion in 2025 and is expected to reach USD 12.87 Billion by 2035, registering a revenue CAGR of 7.2% during the forecast period. Growing international travel activity and increasing awareness of travel-related infectious diseases are supporting market expansion. Governments and public health agencies are strengthening vaccination recommendations and entry requirements for travelers visiting regions with elevated disease risks. According to the World Tourism Organization (UN Tourism), international tourist arrivals have continued to recover across major destinations, increasing demand for preventive healthcare services. At the same time, guidance from the World Health Organization (WHO) and national public health agencies continues to encourage vaccination against diseases such as yellow fever, hepatitis A, typhoid, meningococcal disease, and rabies for travelers visiting specific regions.

GET EXCLUSIVE SAMPLE COPY OF THIS REPORT HERE @ https://www.reportsanddata.com/request-sample/7

KEY GROWTH DRIVERS

The Travelers Vaccines market is benefiting from the recovery of global tourism, business travel, educational mobility, and international workforce movement. Healthcare providers are expanding travel medicine services to address increasing demand for destination-specific immunization programs. Rising awareness regarding disease prevention and growing access to travel health clinics are supporting vaccine uptake across both developed and developing countries. Regulatory requirements for entry into certain countries continue to create demand for vaccines, particularly for diseases such as yellow fever and meningococcal infection. Vaccine manufacturers are also investing in production capacity and distribution networks to improve availability across international markets. For instance, in May 2024, GlaxoSmithKline plc, United Kingdom, announced continued investment in vaccine manufacturing and supply capabilities to support global immunization programs. These are some of the key factors driving revenue growth of the Travelers Vaccines market.

MARKET RESTRAINTS

However, vaccine affordability remains a challenge in several developing regions where travel healthcare services are not widely accessible. Regulatory approval requirements across multiple jurisdictions can increase development costs and delay product launches. Supply chain disruptions affecting vaccine distribution and cold-chain logistics may also impact product availability in certain markets. In addition, vaccine hesitancy among some traveler groups and limited awareness regarding destination-specific vaccination recommendations can reduce adoption rates. These factors are expected to limit Travelers Vaccines market growth to some extent over the forecast period.

SEGMENT HIGHLIGHTS

The hepatitis vaccines segment accounted for the largest revenue share in the market in 2025. Hepatitis A and hepatitis B vaccines are commonly recommended for international travelers visiting regions where disease prevalence remains elevated. Growing awareness regarding foodborne and waterborne disease transmission risks continues to support demand for these vaccines. The widespread availability of hepatitis vaccination programs through hospitals, clinics, and travel health centers has also contributed to segment leadership.

The yellow fever vaccines segment is expected to register the fastest growth during the forecast period. Many countries continue to require proof of yellow fever vaccination for entry from designated risk regions. Increasing travel to Africa and South America, where yellow fever transmission remains a public health concern, is supporting demand for vaccination services. Public health initiatives aimed at preventing outbreaks are expected to further contribute to segment growth.

Get Access to Full summary of the Travelers Vaccines Market report @ https://www.reportsanddata.com/report-detail/travelers-vaccines-market

REGIONAL OUTLOOK

North America

North America accounted for a major share of the Travelers Vaccines market in 2025 due to high international travel volumes, established healthcare infrastructure, and strong awareness regarding preventive healthcare. The United States remains a leading market supported by a large network of travel medicine clinics and vaccination centers. According to the U.S. Centers for Disease Control and Prevention (CDC), millions of U.S. residents travel internationally each year and are advised to receive destination-specific vaccinations based on health risks and local disease prevalence. Major vaccine manufacturers continue to maintain extensive distribution networks across the region.

Europe

Europe represents an important market due to high outbound travel activity and well-developed public healthcare systems. Countries including Germany, France, Italy, and the United Kingdom continue to promote preventive healthcare measures for international travelers. The European Centre for Disease Prevention and Control (ECDC) regularly issues guidance regarding travel-related infectious disease risks, supporting awareness among healthcare providers and travelers. Companies such as GlaxoSmithKline plc continue to play a major role in supplying vaccines across European markets.

Asia Pacific

Asia Pacific is expected to register the fastest revenue growth during the forecast period. Rising disposable incomes, expanding middle-class populations, and increasing international travel activity are driving demand for travel-related healthcare services. Countries such as China, India, Japan, South Korea, and Australia are witnessing growing awareness regarding preventive vaccination before overseas travel. Government investments in healthcare infrastructure and expanding access to vaccination services are further supporting market growth. The region is also becoming an important manufacturing hub for vaccine production, contributing to improved supply availability.

Interested in purchasing this Report? Click here @ https://www.reportsanddata.com/report-pricing/7

Segmentation Insights

Traveler Type Outlook (Revenue, USD Billion, 2025 - 2035)
Business Travelers
Leisure Travelers
Students
Migrant Workers
Pilgrims

End Use Outlook (Revenue, USD Billion, 2025 - 2035)
Adults
Pediatrics

Distribution Channel Outlook (Revenue, USD Billion, 2025 - 2035)
Hospital Pharmacies
Retail Pharmacies
Travel Clinics
Online Booking & Vaccination Platforms

Vaccine Type Outlook (Revenue, USD Billion, 2025 - 2035)
Hepatitis A
Hepatitis B
Typhoid
Yellow Fever
Rabies
Meningococcal
Japanese Encephalitis
Other Travel Vaccines

Regional Outlook (Revenue, USD Billion, 2025 - 2035)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Others
Latin America
Brazil
Others
Middle East and Africa (MEA)
KSA
UAE
South Africa

MEDIA CONTACT
Contact: Debanjan Biswas
Company: Reports and Data
Email: sales@reportsanddata.com
Website: www.reportsanddata.com

ABOUT REPORTS AND DATA
Reports and Data is a market research and consulting firm that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics and industries to help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market.

This release was published on openPR.